Anavex Life Sciences Corp. [NASDAQ: AVXL] slipped around -0.48 points on Thursday, while shares priced at $4.96 at the close of the session, down -8.82%. The company report on November 30, 2020 that Anavex Life Sciences Announces Notice of Allowance for U.S. Patent Application with Expanding Claims Covering ANAVEX®2-73 (blarcamesine) for the Treatment of Rett Syndrome and other Neurodevelopmental Disorders.
Issuance of Its Newest U.S. Patent Will Strengthen Anavex’s Compounds Intellectual Property Portfolio.
Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) disorders, announced it received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for its patent application number 16/717,921 expanding coverage of treatment methods for ANAVEX®2-73 (blarcamesine) and related sigma-1 receptor agonist drug candidates, for treating a range neurodevelopmental disorders including Rett syndrome, autism spectrum disorder, Angelman syndrome, cerebral palsy and multiple sclerosis, among other indications.
Anavex Life Sciences Corp. stock is now 91.51% up from its year-to-date (YTD) trading value. AVXL Stock saw the intraday high of $5.48 and lowest of $4.91 per share. The company’s 52-week high price is 7.69, which means current price is +125.45% above from all time high which was touched on 11/06/20.
Compared to the average trading volume of 1.23M shares, AVXL reached a trading volume of 1145302 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Anavex Life Sciences Corp. [AVXL]?
Ladenburg Thalmann have made an estimate for Anavex Life Sciences Corp. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on September 28, 2020. The new note on the price target was released on February 27, 2020, representing the official price target for Anavex Life Sciences Corp. stock. On May 16, 2018, analysts increased their price target for AVXL shares from 5 to 7.
The Average True Range (ATR) for Anavex Life Sciences Corp. is set at 0.45 The Price to Book ratio for the last quarter was 11.81.
How has AVXL stock performed recently?
Anavex Life Sciences Corp. [AVXL] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -4.62. With this latest performance, AVXL shares dropped by -18.29% in over the last four-week period, additionally plugging by 27.18% over the last 6 months – not to mention a rise of 63.70% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for AVXL stock in for the last two-week period is set at 46.03, with the RSI for the last a single of trading hit 41.64, and the three-weeks RSI is set at 47.68 for Anavex Life Sciences Corp. [AVXL]. The present Moving Average for the last 50 days of trading for this stock 5.08, while it was recorded at 5.27 for the last single week of trading, and 4.21 for the last 200 days.
Anavex Life Sciences Corp. [AVXL]: Deeper insight into the fundamentals
Return on Total Capital for AVXL is now -142.75, given the latest momentum, and Return on Invested Capital for the company is -128.96. Return on Equity for this stock declined to -128.96, with Return on Assets sitting at -105.80.
Reflecting on the efficiency of the workforce at the company, Anavex Life Sciences Corp. [AVXL] managed to generate an average of -$1,643,436 per employee.Anavex Life Sciences Corp.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 4.60 and a Current Ratio set at 4.60.
Earnings analysis for Anavex Life Sciences Corp. [AVXL]
With the latest financial reports released by the company, Anavex Life Sciences Corp. posted -0.07/share EPS, while the average EPS was predicted by analysts to be reported at -0.15/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 53.30%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for AVXL.
Insider trade positions for Anavex Life Sciences Corp. [AVXL]
There are presently around $63 million, or 21.30% of AVXL stock, in the hands of institutional investors. The top three institutional holders of AVXL stocks are: BLACKROCK INC. with ownership of 3,518,845, which is approximately -1.148% of the company’s market cap and around 4.04% of the total institutional ownership; VANGUARD GROUP INC, holding 2,763,882 shares of the stock with an approximate value of $13.71 million in AVXL stocks shares; and STATE STREET CORP, currently with $4.42 million in AVXL stock with ownership of nearly 1.611% of the company’s market capitalization.
Positions in Anavex Life Sciences Corp. stocks held by institutional investors increased at the end of December and at the time of the December reporting period, where 34 institutional holders increased their position in Anavex Life Sciences Corp. [NASDAQ:AVXL] by around 1,422,092 shares. Additionally, 33 investors decreased positions by around 602,938 shares, while 20 investors held positions by with 10,756,321 shares. The mentioned changes placed institutional holdings at 12,781,351 shares, according to the latest SEC report filing. AVXL stock had 11 new institutional investments in for a total of 593,053 shares, while 9 institutional investors sold positions of 195,754 shares during the same period.